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COPD is described by progressive airflow restriction and recurrent acute exacerbations, which is caused by 
inflammatory response occurring in lungs as a result of chronic inhalation of harmful particles and gases. The study was 
designed to determine the link of interleukin-6 (IL-6), adiponectin and visfatin with BMI and oxidant/antioxidant balance in 
Chronic Obstructive Pulmonary Disease (COPD), a systemic disease. The study comprised control (n=20), patients with 
COPD (n=37) from the Chest Diseases Clinic of Firat University Hospital. The serum MDA, IL-6, Visfatin and Adiponectin 
levels were evaluated by ELISA. Also, Pulmonary Function Tests were done. There was no significant difference between 
control and patients with COPD in terms of sex and age averages. On the contrary, BMI levels were statistically 
significantly lower in COPD group compared to the controls. MDA and adiponectin levels were higher, IL-6 and  
visfatin levels were lower in COPD groups contrary to controls. It was thought that the level changes of these parameters 
(MDA, IL-6, visfatin and adiponectin) may be an important factor in the development of COPD and in monitoring the 
treatment of COPD-related diseases. 
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Chronic obstructive pulmonary disease (COPD) is a 
disease characterized by progressive airflow 
limitation and recurrent acute exacerbations, which is 
caused by inflammatory response occurring in lungs 
as a result of chronic inhalation of harmful particles 
and gases1. COPD affects small and large airways in 
lung, lung parenchyma and pulmonary vascular bed, 
and also other systems2.  
Causes of body composition change (fat-free mass, 
fat mass and bone mineral content, etc.) accepted as an 
important cause of comorbidity in COPD3, the increase 
in energy consumption that is associated with respiration 
developing in parallel to the increase in respiratory act, 
negative energy balance caused by the impairment  
in metabolic and functional capacities are used to 
explain this change4. In the pathogenesis of COPD, in 
addition to genetic factors, environmental factors, 
inflammation and especially oxidative stress play  
an important role5. Activated inflammatory cells, 
neutrophils and alveolar macrophages lead to 
endogenous oxidant production in patients. Increased 
oxidative burden damages all the cellular 
macromolecules (lipid, protein and DNA)6. 
Adiponectin, the richest adipokine in human 
plasma, has been reported to have both pro-
inflammatory and anti-inflammatory effects7,8. 
Therefore, while serum level of adiponectin is high in 
some human studies9,10, it is low in others11,12. 
Visfatin is a proinflammatory cytokine which is 
secreted from visceral fat tissue rather than 
subcutaneous fat tissue, exhibits an insulin-like effect 
by binding to insulin receptors and has 
immunomodulatory effects in inflammation, natural 
immunity regulation13. It was reported that evaluated 
the relationship of nesfatin and visfatin with 
inflammation activity, severity of symptoms, and lung 
function in men with emphysema and COPD14. IL-6, 
one of the inflammatory cytokines, increases in 
different lung diseases and is a by-product of ongoing 
inflammation in the lung15. In a study conducted by 
Liang et al., leptin and IL-6 levels in the serum and 
sputum were higher in patients with acute 
exacerbation of COPD compared with stable COPD 
and control patients. Therefore, they were suggested 
that leptin and IL-6 levels were associated with the 
severity of COPD16. 
It was aimed to detect the association of 
interleukin-6 (IL-6), adiponectin and visfatin with 
BMI and oxidant/antioxidant balance in COPD, a 
systemic inflammatory disease. 
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Materials and Methods 
 
Patient selection  
37 patients who were followed with a diagnosis of 
COPD acute attack in the Chest Diseases Clinic of 
Firat University Hospital were included in the study. 
The diagnosis of COPD acute attack was defined as a 
situation which is characterized by an increase in 
respiratory disorder and a decrease in the daily 
performance, change in sputum amount and color, 
exacerbation in coughing, high fever and/or 
deterioration in mental status in a case progressing 
stabile, and which may require change in an ordinary 
drug treatment with acute onset. Age, gender, duration 
of disease and smoking histories of the cases were 
questioned, and their body mass indexes were 
calculated by measuring weight and height. 
The presence of systemic, allergic, neoplastic or 
immunologic diseases, the determination of 
reversibility in pulmonary functions and the presence 
of coexisting lung disease to COPD were considered as 
the exclusion criteria from the study. Control group 
was formed by randomly selecting 20 cases who were 
in the same age group and gender with COPD patients, 
who has normal spirometric lung functions and who 
had no history of lung and systemic infection and 
regular use of drug in the last month. They were also 
nonsmokers. 
Blood was taken from COPD patients for 2 times 
which were in the acute period (1st day and on the 15th 
day after treatment, and 5 mL of blood was taken from 
the healthy control group for 1 times, and serum levels 
were studied in Medical Biochemistry Laboratory. 
From COPD patients and the healthy control group, 
venous blood samples were taken into gelled chemistry 
tubes between at 08:30-09:30 after 10 h of fasting, and 
their serums were separated by centrifuging for 5 min. 
at 4000 rpm. Serum samples were separated into 
portions and stored at −80°C until the day of analysis. 
Samples were studied by warming to room temperature 
(23–25.5°C) after taken out of the deep freezer.  
 
Detection of Malondialdehyde (MDA) 
As an indicator of lipid peroxidation, MDA levels 
were measured using appropriate MDA kit (Immuchrom 
GmbH Company, Hessen, German) by High-
performance liquid chromatography (HPLC). MDA, 
which is converted into fluorescence products with a 
derivatising agent, added reaction solution. The 
absorbance of MDA was measured at 515 nm 
(excitation), at 553 nm (emission) by spectrophotometric 
detector. The results were given as nmol/mL. 
Determination of serum levels of IL-6, Visfatin and Adiponectin 
Serum concentration of IL-6 (Boster Biological 
Technology, Ltd., Pleasanton, CA, EK0410) Visfatin 
(Adipo Bioscience, Santa Clara, CA, USA, SK00121-
01) and adiponectin (Boster Biological Technology, 
Ltd., Pleasanton, CA, EK0595) levels were measured 
by a commercially available sandwich enzyme-linked 
immunosorbent assay according to the manufacturer's 
protocol. Absorbance of standards and samples was 
read at 450 nm. Automatic ELx50 Biotek plate 
washer and ELx800 plate reader was used in ELISA 
studies. Manufacturer average intra-assay and inter-
assay coefficients of variation were <10% for IL-6, 
visfatin and adiponectin. 
 
Measurement of Pulmonary Function Tests 
Pulmonary function tests were performed at least 
three measurements using nose plugs, in a sitting 
position, at room temperature in Firat University Chest 
Diseases Clinic and the best results were evaluated. 
FEV1, FVC and FEV1/FVC ratio were measured and 
recorded. The data was interpreted according to the 
European Respiratory Society estimates. 
 
Statistical Analyses 
All results were presented as means ± SD and 
analyzed using one-way analysis of variance 
(ANOVA). The LSD test was used for comparisons 
between groups. P ≤0.05 was considered statistically 
significant. Statistical analysis was performed using  
the SPSS 22.0 statistical software package (SPSS  
Inc., Chicago, IL, USA) for this purpose. Bivariate 
correlation analysis (calculation of the Pearson 
coefficient) was used to assess the correlation of serum 
visfatin and adiponectin levels to each parameter. 
 
Results 
There was no any statistical difference between the 
patients and the control group in terms of sex and age 
averages. BMI values were statistically significantly 
lower in COPD group compared to the controls  
(P < 0.001). Demographic features of the study group 
are shown in (Table 1). 
Mean FEV1, FVC and FEV1/FVC values of COPD 
patient group (1st, 15th day and total) were quite lower 
Table 1 — Demographic Characteristics of the Study Group 




Age (year) 60.05± 5.71 61.59± 5.91 
Sex (M/F) 20/0 37/0 
BMI (kg/m2) 23.67±1.98 21.16±2.84* 
*P <0.001 compared with control group 




compared to the control group (P< 0.001 for three 
parameters). Serum visfatin and IL-6 levels were 
statistically significant lower in COPD group compared 
to the controls. MDA and adiponectin levels were 
statistically significant higher in patient groups 
compared with controls (Table 2). 
There was a positive correlation between serum IL-6 
levels and visfatin levels (r: 0.330, p=0.046), and a 
negative correlation between adiponectin (r= −0.375,  
P =0.022) patient groups (Table 3). 
 
Discussion 
Decreases in bone mass in the patients with low 
BMI and increase in fatty tissue in obese patients were 
associated with the impairment in health status and 
increased mortality17. It was also indicated that low 
BMI is a risk factor for COPD development18. The 
reducing BMI as a result of dyspnea in COPD, 
inadequate food intake due to the difficulty in food 
digestion and excessive apoptosis in skeletal muscles 
based on systemic inflammation has been defined as an 
independent marker of mortality and morbidity 
secondary to the disease19. The fact that BMI values 
were statistically significantly lower in COPD patient 
group, in which all the patients are male, compared to 
the control group in our study supports the study results 
above. The relationship that we detected between BMI 
values and respiratory functions of the patients with 
COPD exacerbation gives rise to the thought that BMI 
assessment is important in disease pathogenesis. 
Moreover, understanding the weight loss mechanisms 
in COPD and minimizing the weight loss have been 
found important in terms of survival duration and 
fighting against the disease20. 
Oxidative stress and inflammation that are 
characteristic for COPD have synergistic effects on 
muscle breakdown21. As a result of excessive oxidant 
production of oxidant/antioxidant balance and/or 
breakdown of antioxidants in favor of the reduction 
thereof occurs oxidative stress22,23. Oxidative stress not 
only damages lungs but activates molecular mechanisms 
performing lung inflammation, as well24. Increased 
oxidative stress parameters and decreased BMI values in 
our study are parallel to these studies. MDA levels of 
COPD patient groups [1st, 15th day and total) were 
significantly higher than the controls in our study. This 
increase was even more apparent in patients with COPD 
exacerbation. This shows that oxidant effect increasing 
in COPD leads to lipid peroxidation. Similarly, MDA 
levels were statistically significantly high in COPD 
patients25,26. Likewise, in a lot of literature studies, MDA 
levels were higher in acute exacerbation period 
compared to the stable period in COPD patients similar 
to the data of our study. Again in these studies, the 
decreases detected in antioxidant enzyme levels indicate 
that oxidant/antioxidant balance is break down in favor 
of oxidants in COPD patients27,28. 
It is detected that in studies that are made 
considering the fact that pathology is not only limited 
to airways in COPD, but there are also the systemic 
effects, weight loss is associated with inflammatory 
cytokines such as serum IL-6 and TNF- and 
adipocytokines such as serum leptin, adiponectin and 
Table 2 — Pulmonary Function Test Parameters of the control and patient group with COPD (1, 15 days and total), and serum MDA,  
IL-6, visfatin and adiponectin levels 






BMI 23.67±1.98 21.16±2.84* 21.63±2.89** 21.38±2.86* 
FEV1 (%pred) 87.95±4.55 31.05±11.08* 39.19±13.59* 34.76±12.86* 
FVC (%pred) 87.40±4.67 47.32±12.87* 55.55±17.52* 51.07±15.61* 
FEV1/FVC 88.45±5.67 49.27±10.19* 50.13±11.46* 49.66±10.71* 
MDA (nmol/mL) 0.64±0.22 1.61±0.24* 1.36±0.23* 1.50±0.27* 
IL-6 (pg/mL) 1.23±0.42 1.11±0.08** 1.10±0.04** 1.11±0.06** 
Visfatin (ng/mL) 9.71±1.36 8.37±1.26* 8.64±1.32** 8.49±1.29* 
Adiponectin (ng/mL) 22.51±10.69 151.74±93.68* 162.89±104.79* 156.83±98.30* 
*P< 0.001 compared with control group, **P< 0.05 compared with control 
 
Table 3 — Correlation between adipokines and other parameters 
in patients with COPD exacerbations (n=37) 
 Visfatin (ng/mL) Adiponectin(ng/mL) 

























visfatin29,30. It is reported that adiponectin, which is 
among the adipokines regulating the energy 
metabolism and appetite, increases insulin sensitivity 
and the levels decrease in obese individuals as 
inflammatory response31. Anti-inflammatory effect of 
adiponectin manifests itself as the increase in plasma 
adiponectin levels in COPD individuals32. Carolan et al. 
also detected that increased plasma adiponectin levels 
in COPD are associated with lung emphysema and 
low bronchial capacity related to BMI decreasing at 
later ages leads to disease progression32. In our study, 
similarly, serum adiponectin levels were significantly 
higher both in COPD exacerbation and stable COPD 
groups compared to the controls. Significant increase 
of adiponectin levels in COPD groups with low BMI 
is parallel to the mechanisms stated above. These 
results give rise to the thought that hyperinflation and 
low BMI in COPD patients increase serum 
adiponectin levels with anti-inflammatory effect and 
contribute to the defense. 
Intra-abdominal adipose tissue, an active endocrine 
organ, has a positive correlation with pro-
inflammatory adipocytokines (IL-6, TNF-α and 
leptin) regulating insulin sensitivity and negative 
correlation with adiponectin33. When (1st, 15th day and 
total) serum IL-6 levels of COPD patient group were 
compared with the control group, there was a 
statistically significant decrease, and there was a 
negative correlation between decreased IL-6 levels 
and serum adiponectin levels (r = −0.375, P =0.22). 
Except for the increase in acute phase proteins, 
functional effects of IL-6 in circulation has not been 
determined yet, but there is evidence regarding that it 
may be associated with skeletal muscle weakness34. It 
is shown that there is a correlation between the 
increased IL-6 concentrations in circulation and 
systemic inflammation degree in some comorbid 
diseases. Inflammatory mediators such as TNF-α,  
IL-lβ and IL-6 can be accepted as general markers of 
inflammation. However, IL-6 is not a simple 
inflammatory marker and has an active role in the 
pathogenesis of some diseases such as rheumatoid 
arthritis35. Studies claiming that IL-6 has a potential 
role in the pathogenesis in COPD and induced mucus 
IL-6 levels are inversely proportional to FEV136. 
In addition to the studies stating that visfatin levels 
in circulation system of the patients losing excessive 
weight after the stomach surgery37. Both high38 and 
low39 visfatin levels were reported in COPD patient 
groups when compared to the control group. In our 
study, serum visfatin levels of COPD patient group (1st, 
15th day and total) were statistically significantly lower 
when compared to the control group. Visfatin, along 
with TNF-α and IL-6, plays a key role in the regulation 
of inflammatory process40. COPD patient data studying 
on visfatin level are quite contradictory. In addition to 
the studies reporting high visfatin levels in COPD 
patients with low BMI40,41, there are also studies 
detecting decreased visfatin levels14,42. In a study, it 
was reported that there is a positive correlation between 
low plasma visfatin levels and visfatin and IL-6 in 
COPD patients14. Similarly, in our study, there was a 
positive correlation between visfatin and IL-6 levels in 
COPD exacerbation patient group (r =0.330, P =0.046). 
 
Conclusion 
It was suggested that the level changes of MDA,  
IL-6, visfatin and adiponectin may be an important 
factor in the development of COPD. Meanwhile, the 
studies in which the correlation between systemic 
inflammation and weight loss during COPD is 
evaluated, although a lot of inflammatory markers are 
correlated with weight loss and other systems, the 
mechanisms could not be identified clearly.  Methods 
should be developed by considering the effects of 
decreased BMI on the disease severity in the fight 
against COPD. Moreover, while treatment protocols 
for the increased inflammation and oxidative stress are 
developed, thanks to the assessments to be made in 
cytokine and protein changes with pro-inflammatory/ 
anti-inflammatory effect by considering the other 
systems accompanying the disease in addition to the 
respiratory system, early diagnosis and the treatment of 
the accompanying diseases, COPD morbidity and 
mortality can be reduced.  
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